Twist Bioscience Corp TWST revenue by segment, product and geography
In its fiscal year ending 2025-09-30, Twist Bioscience Corp reported revenue across 1 business segments; the largest, Reportable Segment, was $377M, 100.0% of the filed sum (+20.3% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$377M100.0%+20.3% yoy
Members sum to the consolidated $377M for this period.
- Reportable Segment-$136M100.0%-38.3% yoy
Members sum to the consolidated -$136M for this period.
- Ngs Tools$208M55.3%+23.0% yoy
- Synthetic Genes$114M30.2%+22.6% yoy
- Antibody Discovery$23.5M6.2%+15.4% yoy
- Oligo Pools$20.2M5.4%+19.7% yoy
- Dna And Biopharma Libraries$11.2M3.0%-19.7% yoy
Members sum to the consolidated $377M for this period.
- Americas$226M59.9%+16.3% yoy
- EMEA$124M33.0%+34.2% yoy
- Asia Pacific$26.8M7.1%+0.9% yoy
Members sum to the consolidated $377M for this period.
- Reportable Segment$111M100.0%+19.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.